Utah Medical Products offers healthcare solutions for L&D Labor & Delivery, NICU Neonatal Intensive Care, Women's Health, Urology, Surgery & Critical Care. The company operates as a focused niche player with established products recognized in over 100 countries, maintaining strong operational margins and consistent dividend payments despite recent revenue pressures. Its specialized product portfolio and healthcare provider relationships provide competitive moats in targeted markets.
Cyborg Score Rationale
In 2024, Utah Medical Products's revenue was $40.90 million, a decrease of -18.56% compared to the previous year's $50.22 million. While facing near-term revenue headwinds, the company maintains strong fundamentals with high margins and returns on capital. The micro-cap profile and recent sales decline create execution risk, though the specialized market position and established product lines provide resilience.
Top Insights
Revenue declined 18.6% YoY in 2024 to $40.9M, signaling market or competitive headwinds requiring strategic attention
Strong capital efficiency and high post-tax margins indicate quality underlying business despite revenue challenges
Diversified product portfolio across women's health, neonatal care, urology and critical care provides revenue stability across end markets
Micro-cap NASDAQ listing ($200M+ market cap) with low trading volume presents liquidity and visibility challenges for institutional investors
Named Competitors
Surgical devices and energy-based systems — Electrosurgical and vessel sealing devices for surgery
Medical device diversified portfolio — Broad medical device manufacturer across multiple therapeutic areas
Women's health surgical devices — Focused women's health and fertility medical devices
Vascular surgery devices — Vascular and neurosurgical intervention devices
Niche medical devices — Specialty medical device manufacturer
Recent Developments
(July 2025) Board approved quarterly cash dividend of $0.305 per share, demonstrating commitment to shareholder returns